AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02224001 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The Flag Technique
Description: A New Concept in the Tip Plasty of Asian Rhinoplasty : The Flag Technique by Use of Only A Septal Cartilage without Septal Extension Grafts~The investigators propose the new technique, so called 'Flag Technique' by a tip-strut complex in a flag-like shape : using only the septal cartilage as an elongated columellar septal strut graft, a shield graft , bilateral mini-spreader grafts of the upper part in the elongated columellar septal strut graft without the septal extension graft to achieve the desired the result.
Study NCT03050385 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Study NCT03050385 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Study NCT04239612 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical exercise
Description: Regular physical exercise in groups. Circular training: both strength and fitness
Study NCT01573052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlordiazepoxide
Description: 25mg four times daily x 3 days then tapered over 3 days
Study NCT01573052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: 300mg four times daily x 3 days then tapered over 3 days
Study NCT04066231 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIPUN GMS
Description: Motility is measured for 4 hours with the VIPUN Gastric Monitoring System (GMS).
Study NCT04066231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin Lactobionate
Description: Test model: Erythromycin has gastroprokinetic properties. The primary aim of this investigation is to validate the ability of the VIPUN GMS to discriminate between normal and pharmacologically-enhanced fasting gastric motility in healthy adults.~Erythromycin Lactobionate infusion: 200 mg i.v. infusion over a period of 20 minutes. Note: Erythromycin is not labeled as a gastroprokinetic agent in Belgium.
Study NCT01698580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: On-site exercise
Description: The program will consist of progressive balance, including postural orientation and anticipatory postural adjustments sensory-motor activities, and strengthening exercises to enhance balance and postural control and reduce falls. Exercises in the standing position will be prioritised in order to target balance control.Exercises will be both static and dynamic, and will get progressively more challenging, in order to reach the individual optimal level of balance and strength functional status.
Study NCT01698580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home-based exercise
Description: Participants will be provided with a detailed booklet containing safety precautions, instructions and photographs of exercises for use in exercise sessions at home and will be instructed to do the exercises preferably under the supervision of a relative or caregiver, in a suitable place (with good lighting and ventilation) and using proper support (close to a table or chair, or the corner of a wall). In the first four weeks of intervention the patients will stay for 30 minutes after the therapy sessions in order to learn the home exercises. The exercises will be reviewed, if necessary, after each session till the last week of intervention. All necessary equipment to undertake the exercise program will be provided.
Study NCT01698580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational and behavioural
Description: Sessions will address specific environmental and behavioural risk factors delivered by trained health professionals,lasting for 30 minutes and will use appropriate language for lay people.Each meeting will be consisted of a brief introduction on the core day topic with supporting audio-visual or graphic material, followed by group discussion in order to identify the beliefs and attitudes of participants regarding falls and any major restriction or barrier for the implementation of preventive strategies. Participants will be encourage to report their own experiences and beliefs. The activity will always end with the reinforcement of the core message of the session.
Study NCT01698580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Management of modifiable risk factors
Description: Postural hypotension: review of medications that may contribute to postural hypotension;Visual impairment: Participants identified as having visual problems will be referred to an ophthalmologist. The use of four or more medications or the use of psychotropic medication: A review of the risk-benefit of using specific medications will be undertaken, especially psychotropic and anti-hypertensive drugs; Foot problems and shoes: Guidance on the use of proper footwear, nail care and the treatment of cutaneous mycoses will be given; Undernutrition: Participants with a BMI lower than 22 kg / m2 and or a leg calf under 31cm will be oriented to increase their protein and calorie intake and will be referred to a nutritionist.
Study NCT01698580 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The control group will receive a baseline assessment to identify risk factors for falls and will be referred to their clinicians with a report of individual modifiable risk factors to be managed without any specific guidance: referral to routine services, treatments or any specific orientation will be at the discretion of their primary clinicians. So, further management of each participant in the control group will be individualized, with no specific protocol. Interventions will be recorded. Participants will receive a leaflet with basic orientations for fall prevention.
Study NCT02677519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aptensio XR
Description: Orally-administered extended release formulation of methylphenidate; once daily dosing
Study NCT01333930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active O2
Description: oxygenised table water containing at least 20 mg O2 per 500 ml (15-fold higher content in comparison to placebo), further excipients: natural mineral water: carbonic acid, oxygen, sodium, potassium, magnesium, calcium, fluoride, chloride, nitrate, sulfate, hydrocarbonate (according to the summary of analysis)
Study NCT01333930 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Adelholzener Mineralwasser
Description: natural mineral water containing the following ingredients: carbonic acid, sodium, potassium, magnesium, calcium, fluoride, chloride, nitrate, sulphate, hydrocarbonate (according to the summary of analysis)
Study NCT04087850 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Making Socially Accepting Inclusive Classrooms
Description: Using a consultation model, study staff members met with teachers approximately twice per month and observed them an additional two times per month. The goal was to help teachers implement practices that create a socially accepting classroom climate for children.
Study NCT03617224 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TSEBT
Description: The regimen includes a rule-based 3+3 design for escalating regimen intensity of combined TSEBT and pembrolizumab.
Study NCT03617224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSEBT and pembrolizumab
Description: Dose regimens are sequential therapy of TSEBT with Pembrolizumab.
Study NCT01415336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin, Cyclophosphamide
Description: doxorubicin 60 mg/m², iv, day 1; Cyclophosphamide 600 mg/m², iv, day 1; every 3 weeks for 4 cycles
Study NCT01415336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin, Capecitabine
Description: doxorubicin 60 mg/m², iv, day 1; capecitabine 950 mg/m2, twice a day, via oral intake, day 1 to day 14; every 3 weeks for 4 cycles
Study NCT01646489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miravirsen sodium
Description: Miravirsen 7 mg/kg to be administered as single subcutaneous injections for a total of 5 doses over a 5 week treatment period.
Study NCT01646489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telaprevir
Description: Telaprevir 750 mg to be administered as single and multiple oral doses over two 7 day treatment periods.
Study NCT02029898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Study NCT02029898 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride 0,9%
Study NCT01576068 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Spirometry
Description: Spirometry done in high-risk customers of community-pharmacies to detect airflow limitation
Study NCT00858104 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Laser Ablation
Description: Single session with standardized approach: Two fibers, up to 2 laser emissions; nodule volume up to 10 ml are treated by 800 Joules /ml and above 10 ml by 600 Joules/ml.The treatment is performed under local anesthesia and with diazepam sedation.
Study NCT01710319 — intervention group
Intervention type: OTHER
Intervention: blood draw
Description: a blood specimen will be obtained from each patient in the four groups. An optional blood draw after 30 days of initial blood specimen if indicated.
Study NCT00233064 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Lyophilized Palivizumab
Description: Patients will receive 15 mg/kg of lyophilized palivizumab administered intramuscularly every 30 days for a total of 5 injections.
Study NCT00233064 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Liquid Palivizumab
Description: Patients will receive 15 mg/kg of liquid palivizumab administered intramuscularly every 30 days for a total of 5 injections.
Study NCT02703337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered subcutaneously (SC)
Study NCT02703337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC
Study NCT02014337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone and Eribulin in combination
Description: Single Arm, Two Parts Part 1: Dose Escalation Phase to determine MTD and RP2D in up to 20 patients Part 2: Dose Expansion Phase at RP2D in 20 patients
Study NCT04251403 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mucosal Irrigation
Description: Following routine endoscopic evaluation, investigators will utilize the ERBEJET 2 device (ERBE USA Inc), which is commercially available for the treatment of mucosal lesions, to sample cells from the mucosal surface of the stomach. The aspirate will be collected for cytologic/pathologic assessment.
Study NCT01164709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Bortezomib i.v., day 8, 11, 15, 18; 1.3 mg/m2
Study NCT01164709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nelfinavir mesylate
Description: p.o., days 1 to 21; dose level: (625), 1250, 1875, or 2500 mg, 2x/d
Study NCT03028519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3
Study NCT02479646 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MYL-1401H
Study NCT02479646 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU-Neulasta
Study NCT02479646 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: US-Neulasta
Study NCT01880138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: watching animated cartoon before general anesthesia
Study NCT01880138 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: not watching animated cartoon beofre general anaesthesia
Study NCT03390283 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Complete online survey
Study NCT03391921 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine
Description: All patients will receive the 9-valent vaccine against HPV (Gardasil9) intramuscularly: After a first open phase evaluating tolerability of Gardasil9, women will be randomized between two different doses schedules: in the first schedule, women will receive 2 doses at time 0 and 6 months and a third dose between 18-48 months if their antibody levels are insufficient; the second schedule will be 3 doses at 0, 2 and 6 months.
Study NCT03391921 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccine
Description: All patients will receive the 9-valent vaccine against HPV (Gardasil9) intramuscularly: After a first open phase evaluating tolerability of Gardasil9, women will be randomized between two different doses schedules: in the first schedule, women will receive 2 doses at time 0 and 6 months and a third dose between 18-48 months if their antibody levels are insufficient; the second schedule will be 3 doses at 0, 2 and 6 months.
Study NCT01085006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Tranexamic acid in cases, normal saline in controls
Study NCT01085006 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Tranexamic acid in cases, normal saline in controls
Study NCT04562051 — intervention group
Intervention type: OTHER
Intervention: prophylaxis regimen
Description: All recipients were divided into two groups: stratified prophylaxis group based on donors' and recipients' characteristics and routine prophylaxis group based on clinical experience
Study NCT01165216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab, 3 mg
Description: Intervenous (IV) injection, administered every 3 weeks for up to 6 cycles
Study NCT01165216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab, 10 mg
Description: IV injection, administered every 3 weeks for up to 6 cycles
Study NCT01165216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV injection, 175 mg/m\^2, administered every 3 weeks for up to 6 cycles
Study NCT01165216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV injection, AUC=6, administered every 3 weeks for up to 6 cycles. (AUC=area under the concentration curve)
Study NCT02861885 — intervention group
Intervention type: OTHER
Intervention: Chromoendoscopy
Description: Colonoscopy will run in accordance with standard procedure, including air insufflation throughout the endoscope rise. The endoscope will be a Olympus NBI videoscope (180 series and latest). First, progression will run until caecum without systematic terminal ileum intubation. Polyps will be searched out during descent phase. The patient will be eligible as soon as the operator suspects an ascendant colon SSL with white light. The operator will have to initiate the WLI colonoscopy. If a SSL is suspected in the colon, the operator will run at the same time, a NBI colon examination, then an indigo carmine chromoendoscopy colon examination. Each lesion will be pictured before and after mucus clean-up. Lesions biopsy or resection will be ran in accordance with standard procedure.
Study NCT02844868 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: During the first 20 min of training program, patient will have active tCDS : the patient received a 2 mA anodal tDCS over the lower limb ipsilesional motor area. The anodal electrode was positioned on the hotspot previously identified with TMS. The cathode was placed above the contralesional orbit.
Study NCT02844868 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: During the first 20 min of training program, patient will have sham tCDS : the patient received a 2 mA anodal tDCS (only during the first and the last 30 seconds of the stimulation) and then, patient will have sham tDCS. The anodal electrode was positioned on the hotspot previously identified with TMS. The cathode was placed above the contralesional orbit.
Study NCT03756324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHPM (Chinese Herbal Patent Medicine )
Description: Pugongying (Herba Taraxaci) granules is named as Pugongying Granules in China and produced by Kunming pharmaceutical factory co. LTD. The form is granules, and the participants will take the medicine after dissolved as 15g/tid for 3 days, and the investigators will follow them up for 7 days when the participants are stopped administrating.
Study NCT03756324 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics Cefdinir Capsules
Description: Cefdinir Capsules is also named as Cefdinir and produced by Astellas Pharma Inc. The form is capsule, and participants will take orally the capsules with water as 0.1g/tid for 3 days, and the investigators will follow them up for 7 days when the participants are stopped administrating.
Study NCT03756324 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Doctors will give suggestions and the medical orders to all participants, including dietary, emotional regulation and the knowledge of breast-feeding.
Study NCT03756324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Doctors will give suggestions and the medical orders to all participants, including dietary, emotional regulation and the knowledge of breast-feeding.
Study NCT03756324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics Cefdinir Capsules
Description: Cefdinir Capsules is also named as Cefdinir and produced by Astellas Pharma Inc. The form is capsule, and participants will take orally the capsules with water as 0.1g/tid for 2 days, and the investigators will follow them up for 7 days when the participants are stopped administrating.
Study NCT03801057 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MPH_active
Description: One daily intake at breakfast of supplementary marine protein hydrolysate (MPH), a dosage of 2400 mg, duration 6 weeks. The form is powder, flavored with lemon, and to be mixed with 100 ml water. Random sequence of arms.
Study NCT03801057 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: MPH_placebo
Description: One daily intake at breakfast of supplementary placebo, a dosage of 2400 mg, duration 6 weeks. The form is powder, flavored with lemon, and to be mixed with 100 ml water.
Study NCT04765319 — intervention group
Intervention type: BEHAVIORAL
Intervention: CPT for PTSD
Description: Evidence based psychotherapy for PTSD
Study NCT02422199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrotinib
Study NCT02422199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lapatinib
Study NCT02422199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Study NCT02422199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study NCT03124004 — intervention group
Intervention type: PROCEDURE
Intervention: periodontal debridement
Description: with ultrasonic device supragingival and subgingival full-mouth debridement is provided
Study NCT03711695 — intervention group
Intervention type: DEVICE
Intervention: iBeat wristwatch device
Description: The participant will be asked to wear one iBeat wristwatch device on each arm during the planned procedure.
Study NCT01077050 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SciBase III Electrical Impedance Spectrometer
Description: SciBase III Electrical Impedance Spectrometer is based on Electrical Impedance Spectroscopy (EIS). EIS is a measure of the overall resistance within a skin tissue, at alternating currents of various frequencies. Enrolled subject will undergo skin measurements with SciBase III Electrical Impedance Spectrometer. The relevant skin lesion(s) will be excised and diagnosed as per routine treatment.
Study NCT03007225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trans-arterial chemoembolization (TACE)
Description: TACE procedures were performed by experienced radiologists by fluoroscopy. The femoral artery was catheterized under local anesthesia, with a 4F catheter with Copra head configuration. Conventional angiography of the Coeliac and Hepatic arteries to delineate the feeding arteries of the tumors and to exclude portal venous shunting. Then vascular catheter was inserted super-selectively into the branch of the hepatic artery that is the main feeder of the tumor. Chemoembolization then was performed.~Ten milliliters of Lipiodol was mixed with 100 mg of Doxorubicin hydrochloride and 5ml of Urografin emulsified to create a milky solution. The emulsion slowly was infused into the tumour Gel foam embolization was performed by cutting gel foam sheets into small pledges mannully then mixed with a contrast material and an impirical antibiotic (gentamycin 80 mg). Injection of the mixture slowly under fluoroscopy guidance till complete stasis was achieved.
Study NCT03007225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TACE with Drug Eluting Beads procedure
Description: The same was done as cTACE till the super selective catheterization of the feeding artery.~Loading of the beads with Doxorubicin hydrochloride (100-150 mg) was done in vitro an hour before the beginning of catheterization. The loaded beads were then aspirated from the vial into a syringe filled with nonionic contrast medium. Once the feeding artery was identified and catheter was in placement, the loaded beads were infused slowly under fluoroscopic guidance. Two different sizes of DC beads were used, 100-300 μm and 300-500. Starting with the smaller sized beads to occlude the tumoral bed followed by the larger sized one to embolize the proximal vessels. The injection of the loaded beads was performed as selective as possible using either a4F diagnostic catheter (Cobra head catheter; Cordis, USA) or 2.7F microcatheter (Progreat; Terumo, Japan).
Study NCT02685267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Study NCT02685267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Study NCT02685267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone